NCT05892757View on ClinicalTrials.gov

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Atogepant

Oral Tablet

DRUG

Ubrogepant

Oral Tablet

Trial Locations (3)

65802

Bio-Kinetic Clinical Applications, LLC /ID# 255452, Springfield

78209

Icon /Id# 257524, San Antonio

84124

Icon /Id# 257525, Salt Lake City

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY